# Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

> **NCT05422092** · NA · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 80 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus With Complication

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT05422092
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-20
- **Primary completion:** 2023-01
- **Final completion:** 2023-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422092, "Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05422092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*